Bree Coven Foster

1 week ago | drugdiscoverynews.com | Bree Coven Foster

Synthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods. Credit: iStock.com/ktsimageSynthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods.

1 week ago | drugdiscoverynews.com | Bree Coven Foster

In the world of drug development, securing timely access to fill/finish services can often pose a critical bottleneck, especially for clinical trials requiring small-volume production. Fill/finish refers to the final steps in the production of injectable pharmaceutical drug substances, including the process of filling vials with a drug substance, sealing them, and ensuring they are sterile and ready for use in clinical settings.

2 weeks ago | drugdiscoverynews.com | Bree Coven Foster

Duchenne muscular dystrophy (DMD) has long been understood as a disease driven by the absence of dystrophin, a protein essential for maintaining muscle integrity. Most therapeutic efforts have focused on restoring dystrophin through gene therapy, exon-skipping, or other genetic approaches. However, emerging research suggests that dystrophin’s role extends beyond structural support — it also plays a critical part in regulating muscle regeneration.

2 weeks ago | drugdiscoverynews.com | Bree Coven Foster

From understanding immune responses to screening new drug candidates, flow cytometry plays a critical role in modern biomedical research. By rapidly analyzing thousands of cells per second, researchers can gather precise, multiparametric data at the single-cell level. Recent innovations in automation and high-throughput screening have further expanded the technology’s potential, making it a powerful tool for drug discovery.

Nov 9, 2023 | dev.alto-marketing.com | Bree Coven Foster |Naomi Buckland

Every year, around 56,000 women in the UK are diagnosed with breast cancer – about 150 a day [1]. While significant progress has been made in diagnosis, treatment, and survival rates, this disease still claims around 11,500 lives annually. However, there’s promising news on the horizon, particularly for women at an increased risk of breast cancer. Anastrozole, a well-established breast cancer treatment, has now been licensed for a new purpose: prevention [2].